gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NEOTechnologyTesting Laboratories

NeoGenomics, Inc. (NEO)

$17.02+1.13%
Close Nov 4, 2026 · split-adjusted
Oct 30, 2026$17.38▲ 77.71% in range
Nov 3, 2025Low $7.19 · High $19.91Oct 30, 2026
What changed · written from our data
As of Nov 4, 2026

NeoGenomics closed at $17.02 on Nov 4, up 1.13%, 14.5% below its 52-week closing high. Volume of 417.2K shares was 0.21× its 20-day average (below normal).

Split-adjusted performance: +3.1% over one month, +91.5% over six months, +74.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $209.25M, up 11.4% from a year earlier, with a net margin of -3.6%.

Short interest was 14.2M shares at the Oct 15 settlement (11.3% of float, 6.0 days to cover).

Market cap$2.20B129.4M shares
Revenue · quarter$209.3M+11.4% YoY
Diluted EPS$-0.06—
P/E · TTM—P/S 2.8×
Net margin-3.6%Gross 46.2%
Dividend yieldNone
52-week range7.19 – 19.91−14.5% from high
Volume417.2K0.21× 20-day avg
Volatility · 60d53.5%Annualised
Short % of float11.3%6.0 days to cover
Net cash-$241.3MCash $139.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.4%1M +3.1%3M +9.4%6M +91.5%YTD +44.7%1Y +74.0%3Y +25.1%5Y −61.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Testing Laboratories

Percentile among 3 companies (100 = best)

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Industry medians: 6-month return +32.8%, revenue growth +8.3%, net margin −3.6%, P/E 31.1×.

Short interest

Details →
Shares short14.2M+0.5% vs prior
Days to cover6.0Settled Oct 15
% of float11.3%
Short vol. 10d51.8%of daily volume

Closest peers by size in Testing Laboratories

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NEONeoGenomics$17.02+1.13%+91.5%+11.4%−3.6%—$2.20B
ULSUL Solutions$77.79−3.25%−25.8%+5.2%30.1%31.1$15.70BCompare
AIDX20/20 Biolabs$0.2472+5.21%——−376.8%—$3.2MCompare

News about NeoGenomics

All news →
NeoGenomics (NEO) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · Oct 28, 2026▲ Positive

Quick answers

What does NeoGenomics do?
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
What is NEO's market cap?
$2.20B, based on the Nov 4 close of $17.02.
Does NeoGenomics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NEO is sold short?
14.2M shares, 11.3% of float, as of Oct 15, 2026.
What sector is NEO in?
Technology, in the Testing Laboratories industry.

About NeoGenomics

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

HQ: Fort Myers, FL2,500 employeesListed Jan 25, 1996neogenomics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology